Dr. Gay C Gilmore, M.D. General Practice Medicare: Not Enrolled in Medicare Practice Location: 211 E. Belmont Rd., Crawford, NE 69339 Phone: 308-665-1546 |
News Archive
Fujitsu Laboratories Ltd. and Fujitsu Limited today announced the development of molecular simulation technology for drug discovery that can accurately estimate binding affinity, which represents the degree to which proteins that can cause diseases (target proteins) bind to chemical substances that could become candidate drugs.
Barbecued, stir-fried or roasted, there's no doubt that Aussies love their meat. Consuming on average nearly 100 kilograms of meat per person per year, Australians are among the top meat consumers worldwide.
Cytheris SA and the Cancer Immunotherapy Trials Network, a new initiative in immunotherapy funded by the National Cancer Institute with its Central Operations and Statistical Center headquartered at Fred Hutchinson Cancer Research Center, Seattle, Washington, today announced the selection of recombinant human interleukin-7, the investigational multifunctional cytokine under development by Cytheris, as one of the first immunotherapeutic agents proposed for initial clinical trials at network institutions.
Bristol-Myers Squibb Company announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) of BARACLUDE for the treatment of chronic hepatitis B (CHB) in adult patients with decompensated liver disease.
Heart failure is one of the world's most frequent causes of death - caused by conditions such as diabetes and obesity. With people who are overweight, the heart has to do more work in order to pump the blood through the circulatory system and this causes an increase in blood pressure.
› Verified 5 days ago